Weil has been recognized with two awards at the 2022 International Financial Law Review Asia-Pacific Awards, highlighting the market-leading dealmaking expertise of Weil Asia’s Private Equity practice and its attorneys.

Weil received honors for its work as international counsel on the landmark US$4.76 billion take-private of leading plasma producer China Biologic Products Holdings, which has been named “Deal of the Year – Private Equity.” The Weil team members involved in this transaction include Chris Welty and Jie Yuan.

The IFLR Asia-Pacific Awards recognize the year’s most innovative and accomplished deals, legal teams and attorneys in the Asia-Pacific region.